Veritable’s vTv Therapeutics VTVT Stock Holding History

Veritable’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,073	Closed	-$180K	–	809
2023 Q2	$180K	Hold	6,073	–	–	﹤0.01%	857
2023 Q1	$196K	Hold	6,073	–	–	﹤0.01%	853
2022 Q4	$161K	Buy	6,073 +5,550	+1,061%	+$184K	﹤0.01%	836
2022 Q3	$20K	Hold	523	–	–	﹤0.01%	789
2022 Q2	$16K	Hold	523	–	–	﹤0.01%	894
2022 Q1	$15K	Hold	523	–	–	﹤0.01%	906
2021 Q4	$21K	Hold	523	–	–	﹤0.01%	908
2021 Q3	$32K	Hold	523	–	–	﹤0.01%	877
2021 Q2	$48K	Buy	+523	New	+$53K	﹤0.01%	863

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

SQA

Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return

Veritable's VTVT Position: Q3 2023 in Review

Veritable sold out of vTv Therapeutics (VTVT) in Q3 2023, closing a stake of 6,073 shares — an estimated $180K sold.

Veritable first reported a position in VTVT in Q2 2021 and held it in 9 quarters. The position peaked at $196K in Q1 2023. 24 funds tracked by Wall St. Rank hold VTVT as of Q3 2023.

Veritable reported no remaining vTv Therapeutics position as of Q3 2023 after selling out during the quarter.
Veritable sold 6,073 vTv Therapeutics shares in Q3 2023, an estimated $180K.
Veritable first reported a position in vTv Therapeutics in Q2 2021 and held it in 9 quarters.
Veritable's vTv Therapeutics position peaked at $196K in Q1 2023.
24 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.